MINI TREK RX 1.20 mm Coronary Dilatation Catheter
DeviceEnlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
NCT Number: NCT01186198
This is a prospective, single-arm, open-label, multi-center, observational study to assess the acute safety and efficacy of MINI TREK RX 1.20 mm for enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Scripps Green Hospital, La Jolla, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
General Inclusion Criteria
Angiographic Inclusion Criteria
All angiographic inclusion criteria are based on visual estimation.
Exclusion criteria
General Exclusion Criteria
Angiographic Exclusion Criteria
All angiographic exclusion criteria are based on visual estimation.
Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
Time frame: On Day 0 (From the start to end of the interventional procedure)
Procedure success was defined as meeting all the following after single or multiple attempts:
Time frame: On Day 0 (From the start to end of the interventional procedure)
Device Success was defined as meeting all the following after single or multiple attempts:
Time frame: On Day 0 (From the start to end of the interventional procedure)
Lesion Success was defined as meeting all the following after single or multiple attempts:
Time frame: On Day 0 (From the start to end of the interventional procedure)
The following parameters were assessed by either an angiographic core laboratory or the investigator at the site
Time frame: In-Hospital (1 - 3 Days)
In-hospital MACE was defined as the composite of all deaths, myocardial infarction (MI), and clinically indicated target lesion revascularization (CI-TLR) by coronary artery bypass graft surgery (CABG) or PCI during the hospitalization for the index procedure
Time frame: In-Hospital (1 - 3 Days)
In-hospital TLF was defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), and CI-TLR by CABG or PCI during the hospitalization for the index procedure
Time frame: In-Hospital (1 - 3 Days)
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.
Angiographic confirmation involves presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent and presence of at least 1 of the following criteria within 48-hours:
Acute onset of ischemic symptoms at rest; New ischemic ECG changes that suggest acute ischemia; Typical rise and fall in cardiac biomarkers; Non-occlusive; Occlusive thrombus
Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy is a pathological confirmation.
Probable stent thrombosis is considered to have occur after intracoronary stenting in case of any unexplained death within the first 30 days or any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause
Abbott Medical Devices
Industry
Acronym: CROSS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02681016
Arterial Occlusive Diseases, Arteriosclerosis
Novosibirsk, Russia
View Trial DetailsNCT02769650
Arterial Occlusive Diseases, Arteriosclerosis
Novosibirsk, Russia
View Trial DetailsNCT02708329
Arterial Occlusive Diseases, Arteriosclerosis
Novosibirsk, Russia
View Trial DetailsNCT07579624
Acute Coronary Syndrome, Acute Coronary Syndromes
Moscow, Russia
View Trial Details